By Nate Wolf

Viatris was falling Friday after the pharmaceutical company announced that its eye inflammation treatment didn't meet its target in a late-stage trial.

Viatris' ophthalmic ointment for patients with blepharitis, a condition causing irritation and swelling of the eyelids, failed to fully clear debris from the eyes in the six-week study, the company said.

Shares were falling 4.1% in premarket trading Friday following the announcement. The stock had declined 26% so far this year as of Thursday's close.

"Given that the study did not meet its objective for patients suffering from blepharitis, we are evaluating the appropriate next steps for the Phase 3 program," said Philippe Martin, Viatris' chief research and development officer.

Write to Nate Wolf at nate.wolf@barrons.com

This content was created by Barron's, which is operated by Dow Jones & Co. Barron's is published independently from Dow Jones Newswires and The Wall Street Journal.

(END) Dow Jones Newswires

July 18, 2025 08:47 ET (12:47 GMT)

Copyright (c) 2025 Dow Jones & Company, Inc.